566 related articles for article (PubMed ID: 22131333)
1. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade.
Moon JB; Kim JH; Kim K; Youn BU; Ko A; Lee SY; Kim N
J Immunol; 2012 Jan; 188(1):163-9. PubMed ID: 22131333
[TBL] [Abstract][Full Text] [Related]
2. PDK1 is important lipid kinase for RANKL-induced osteoclast formation and function via the regulation of the Akt-GSK3β-NFATc1 signaling cascade.
Xiao D; Zhou Q; Gao Y; Cao B; Zhang Q; Zeng G; Zong S
J Cell Biochem; 2020 Nov; 121(11):4542-4557. PubMed ID: 32048762
[TBL] [Abstract][Full Text] [Related]
3. Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction.
Kim K; Kim JH; Youn BU; Jin HM; Kim N
J Immunol; 2010 Dec; 185(12):7460-6. PubMed ID: 21068407
[TBL] [Abstract][Full Text] [Related]
4. Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
Kim JY; Oh HM; Kwak SC; Cheon YH; Lee MS; Rho MC; Oh J
Biol Pharm Bull; 2015; 38(1):66-74. PubMed ID: 25744460
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of glycogen synthase kinase-3β is required for osteoclast differentiation.
Jang HD; Shin JH; Park DR; Hong JH; Yoon K; Ko R; Ko CY; Kim HS; Jeong D; Kim N; Lee SY
J Biol Chem; 2011 Nov; 286(45):39043-50. PubMed ID: 21949120
[TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic hnRNPK interacts with GSK3β and is essential for the osteoclast differentiation.
Fan X; Xiong H; Wei J; Gao X; Feng Y; Liu X; Zhang G; He QY; Xu J; Liu L
Sci Rep; 2015 Dec; 5():17732. PubMed ID: 26638989
[TBL] [Abstract][Full Text] [Related]
7. Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.
Lin X; Xiao Y; Chen Z; Ma J; Qiu W; Zhang K; Xu F; Dang K; Qian A
Mol Cell Endocrinol; 2019 Aug; 494():110494. PubMed ID: 31260729
[TBL] [Abstract][Full Text] [Related]
8. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
9. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
10. 9-Hydroxy-6,7-dimethoxydalbergiquinol inhibits osteoclast differentiation through down-regulation of Akt, c-Fos and NFATc1.
Kim JY; Kim JY; Cheon YH; Kwak SC; Baek JM; Kim YC; Yoon KH; Oh J; Lee MS
Int Immunopharmacol; 2014 May; 20(1):213-20. PubMed ID: 24630975
[TBL] [Abstract][Full Text] [Related]
11. miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway.
Zhao C; Sun W; Zhang P; Ling S; Li Y; Zhao D; Peng J; Wang A; Li Q; Song J; Wang C; Xu X; Xu Z; Zhong G; Han B; Chang YZ; Li Y
RNA Biol; 2015; 12(3):343-53. PubMed ID: 25826666
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
14. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
[TBL] [Abstract][Full Text] [Related]
17. Effects of moderate intensity static magnetic fields on osteoclastic differentiation in mouse bone marrow cells.
Kim EC; Park J; Noh G; Park SJ; Noh K; Kwon IK; Ahn SJ
Bioelectromagnetics; 2018 Jul; 39(5):394-404. PubMed ID: 29709064
[TBL] [Abstract][Full Text] [Related]
18. GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras/ERK pathway.
Lee MS; Kim HS; Yeon JT; Choi SW; Chun CH; Kwak HB; Oh J
J Immunol; 2009 Sep; 183(5):3390-9. PubMed ID: 19641137
[TBL] [Abstract][Full Text] [Related]
19. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
20. Idelalisib inhibits osteoclast differentiation and pre-osteoclast migration by blocking the PI3Kδ-Akt-c-Fos/NFATc1 signaling cascade.
Yeon JT; Kim KJ; Son YJ; Park SJ; Kim SH
Arch Pharm Res; 2019 Aug; 42(8):712-721. PubMed ID: 31161369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
